Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:08:01.981Z.
Calculation as of: 2026-10-06T16:08:01.981Z.
Quote observation: 2026-10-06T16:02:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 00a42066d9f3872c54bfb6b46d2066e515b5a7a19eafcedb0603fbeaffc1d64d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2021-02-03.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$68.60M
Price/FCF Ratio
0.55
TTM Avg
0.74
3Y Avg
0.74
5Y Avg
0.74
Market Cap
$67.38M
Price/FCF Ratio
N/A
TTM Avg
17.09
3Y Avg
24.44
5Y Avg
36.17
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MindWalk Holdings Corp. (HYFT) | $70.39M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | 0.55 | 0.74 | 0.74 | 0.74 |
| iBio, Inc. (IBIO)vs › | $67.84M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $67.38M | N/A | 17.09 | 24.44 | 36.17 |
| Gain Therapeutics, Inc. (GANX)vs › | $74.43M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $66.45M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $66.27M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.71M | N/A | 35.77 | 35.77 | 35.77 |
| Hyperfine, Inc. (HYPR)vs › | $76.50M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.10M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2021-02-03 | 1758.87 |
| 2021-02-02 | 1829.58 |
| 2021-02-01 | 1831.83 |
| 2021-01-29 | 1908.15 |
| 2021-01-28 | 1908.15 |
| 2021-01-27 | 1745.40 |
| 2021-01-26 | 1743.15 |
| 2021-01-25 | 1706.11 |
| 2021-01-22 | 1767.85 |
| 2021-01-21 | 1801.52 |
| 2021-01-20 | 1838.56 |
| 2021-01-19 | 1679.17 |
| 2021-01-15 | 1644.38 |
| 2021-01-14 | 1682.54 |
| 2021-01-13 | 1679.17 |
| 2021-01-12 | 1745.40 |
| 2021-01-11 | 1863.25 |
| 2021-01-08 | 1847.54 |
| 2021-01-07 | 1807.13 |
| 2021-01-06 | 1809.38 |
| 2021-01-05 | 1877.85 |
| 2021-01-04 | 1504.07 |
| 2020-12-31 | 1678.05 |
| 2020-12-30 | 1793.66 |
| 2020-12-29 | 2098.97 |
| 2020-12-28 | 2087.74 |
| 2020-12-24 | 1839.68 |
| 2020-12-23 | 1605.09 |
| 2020-12-22 | 1278.46 |
| 2020-12-21 | 1240.30 |
| 2020-12-18 | 1240.30 |
| 2020-12-17 | 1212.24 |
| 2020-12-16 | 1189.79 |
| 2020-12-15 | 1229.07 |
| 2020-12-14 | 1234.69 |
| 2020-12-11 | 1051.73 |
| 2020-12-10 | 821.63 |
| 2020-12-09 | 813.77 |
| 2020-12-08 | 840.71 |
| 2020-12-07 | 851.93 |
| 2020-12-04 | 829.49 |
| 2020-12-03 | 827.24 |
| 2020-12-02 | 821.63 |
| 2020-12-01 | 872.14 |
| 2020-11-30 | 841.83 |
| 2020-11-27 | 859.79 |
| 2020-11-25 | 877.75 |
| 2020-11-24 | 891.22 |
| 2020-11-23 | 826.12 |
| 2020-11-20 | 720.61 |
| 2020-11-19 | 712.75 |
| 2020-11-18 | 695.91 |
| 2020-11-17 | 690.30 |
| 2020-11-16 | 712.75 |
| 2020-11-13 | 774.49 |
| 2020-11-12 | 791.32 |
| 2020-11-11 | 814.89 |
| 2020-11-10 | 796.93 |
| 2020-11-09 | 695.91 |
| 2020-11-06 | 895.71 |
| 2020-11-05 | 886.73 |
| 2020-11-04 | 942.85 |
| 2020-11-03 | 893.46 |
| 2020-11-02 | 882.24 |
